Skip to main
ZTS

Zoetis (ZTS) Stock Forecast & Price Target

Zoetis (ZTS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 22%
Hold 56%
Sell 0%
Strong Sell 0%

Bulls say

Zoetis has demonstrated significant growth in its Petcare division, evidenced by a remarkable increase in enrollment in the Zoetis Petcare Rewards program, which surged from 708,000 participants in 2018 to 2.5 million in the most recent reporting period, supported by over $120 million in investments made in 2023. The company's revenue from its flagship product, Simparica, reached $356 million in Q3, showing a year-over-year growth of 7%, while key dermatology products also contributed positively with a combined global revenue of $469 million, reflecting a 3% increase year-over-year. This robust performance in both revenue growth and strategic investments in customer engagement highlights Zoetis's strong market position and continuing momentum in the animal health sector.

Bears say

Zoetis has revised its revenue guidance for 2025 downward to a range of $9.400 billion to $9.475 billion, reflecting a decline in expected organic operational growth from previous estimates. The company experienced an 11% year-over-year decline in its osteoarthritis pain business due to negative publicity regarding the safety profile of its product, Librela, which has contributed to overall sales pressures. Additionally, the company's Q3'25 results fell below expectations, showing stagnation in the key companion animal health segment, driven by increased competition and a decline in veterinary clinic visits, further indicating challenges in maintaining revenue growth.

Zoetis (ZTS) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 22% recommend Buy, 56% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zoetis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zoetis (ZTS) Forecast

Analysts have given Zoetis (ZTS) a Buy based on their latest research and market trends.

According to 9 analysts, Zoetis (ZTS) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $158, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $158, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zoetis (ZTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.